Last reviewed · How we verify
Bromexine (BROMHEXINE)
At a glance
| Generic name | BROMHEXINE |
|---|---|
| Drug class | bromhexine |
| Target | Cytochrome P450 2D6, Sigma non-opioid intracellular receptor 1, Sodium-dependent serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3) (NA)
- A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions (PHASE3)
- An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III (PHASE2,PHASE3)
- Ambroxol as a Disease-modifying Treatment in GBA-PD (PHASE2)
- Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults (PHASE1)
- Ambroxol to Slow Progression in Parkinson Disease (PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
- Ambroxol as a Treatment for Parkinson's Disease Dementia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |